DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Epidemiology

We help you understand the complete disease landscape and size global markets with real-world data. Learn how to:

  • Benchmark your forecasts with data on the total potential and addressable market
  • Validate your investments using bottom-up forecasting
  • Identify growth opportunities and understand how populations will change over time
  • Track disease stages, subpopulations, and treatment flow
  • Confidently estimate drug-treated populations with additional insights from therapeutic experts and primary market research; and
  • Obtain direct access to our team of epidemiologists for a real-time response to your questions.

 

Schedule a demo

Methodology

  • Coverage of 170+ indications and biomarkers across 5,400 patient segments covered globally. This includes 108 indications with drug-treated populations reported across 27 countries; 79 indications with coverage across 45 countries; and 63 indications with burden-of-disease (lifetime DALYs gained) estimates.
  • Transparent and validated bottom-up methods with proprietary models for exposure-based forecasting
  • Global coverage using validated models of epidemiological transition and geographical extrapolation
  • Estimates based on combinations of publicly available studies, disease registries, and in-house real world data

Only DRG’s Epidemiology forecasts at the total, diagnosed, and drug-treated levels – providing the complete market picture

The foundation for sizing market potential, profiling patient segments and informing confident forecast-based business decisions.

Total Population

The broadest actual – not extrapolated – geographic coverage and most granular population segments for oncology, rare and niche diseases, and beyond.